Results 111 to 120 of about 476,894 (337)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system

Frontiers in Oncology
BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation.
Sentai Wang, Hewen Chen, Yuying Zhou, Jianfeng Chen, Jiwei Cao   +4 more
doaj   +1 more source

VA releases adverse event data: Clinicians must report to nationwide system [PDF]

, 2000
Nancy Tarleton Landis
openalex   +1 more source

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun, Lingling Cui, Robert Terkeltaub, Ying Chen, Xinde Li, Xiaoyu Cheng, Tian Liu, Nicola Dalbeth, Changgui Li   +8 more
wiley   +1 more source

Concomitant Risk Factors in Reports of Torsades de Pointes Associated with Macrolide Use: Review of the United States Food and Drug Administration Adverse Event Reporting System [PDF]

, 2002
Douglas Shaffer, Sarah Singer, Joyce A. Korvick, Peter K. Honig   +3 more
openalex   +1 more source

Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis

Arthritis Care &Research, EarlyView.
Objective Our objective was to examine the relationship between colchicine plasma concentrations and clinical and demographic factors and to determine the relationship between colchicine concentrations and colchicine efficacy and colchicine‐specific adverse events.
Lisa K. Stamp, Anne Horne, Borislav Mihov, Jill Drake, Janine Haslett, Peter Chapman, Daniel F. B. Wright, Christopher Frampton, Nicola Dalbeth   +8 more
wiley   +1 more source

Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system

Frontiers in Pharmacology
IntroductionDrug trials in neonates are scarce, and the neonates may consequently be at risk of adverse drug reactions (ADRs). Spontaneous ADR reporting is an important tool for expanding the knowledge on drug safety in neonates.
Pernille Kähler Byskov, Christoffer Storm Baden, Jon Trærup Andersen, Jon Trærup Andersen, Espen Jimenez-Solem, Espen Jimenez-Solem, Ramus Huan Olsen, Ramus Huan Olsen, Christina Gade, Christina Gade, Ulrik Lausten-Thomsen   +10 more
doaj   +1 more source

Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 [PDF]

, 2004
Elizabeth Begier, Dale R. Burwen, Penina Haber, Robert Ball   +3 more
openalex   +1 more source

Analysis of CFSAN Adverse Event Reporting System and Twitter

, 2019
For the public health monitoring, FDA is releasing the public data for consumer complaint data. This CARES database contains information on product complaint reports submitted to FDA. It includes dietary supplements and food adversary incidents. Also, the FDA is trying to utilize SNS data like Twitter as real-time monitoring tools. In this analysis, we
openaire   +2 more sources

Understanding Contributors of Resilience in Youth With Childhood‐Onset Systemic Lupus Erythematosus Through a Socioecological Lens: A Mixed‐Methods Study

Arthritis Care &Research, EarlyView.
Objective This study aimed to identify themes contributing to resilience in childhood‐onset systemic lupus erythematosus (cSLE), distinguish between profiles of resilience, and examine how they relate to underlying themes and patient characteristics. Methods We conducted a mixed‐methods study of 21 patients with cSLE aged 11 to 19 years at a Canadian ...
Isabella Zaffino, Louise Boulard, Joanna Law, Asha Jeyanathan, Lawrence Ng, Sandra Williams‐Reid, Kiah Reid, Angela Cortes, Eugene Cortes, Ashley Danguecan, Deborah M. Levy, Linda T. Hiraki, Andrea M. Knight   +12 more
wiley   +1 more source

Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta‐Analysis

Arthritis Care &Research, EarlyView.
Objective Gastrointestinal perforation (GIP) is a rare and life‐threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta‐analysis approach.
Thipsukhon Sathapanasiri, Manuel Meraz, Hamraz Mokri, Sajesh K Veettil, Karn Wijarnpreecha, Naomi Schlesinger, Arthur Kavanaugh, Nathorn Chaiyakunapruk   +7 more
wiley   +1 more source